DelveInsight’s “End Stage Renal Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the End Stage Renal Disease, historical and forecasted epidemiology as well as the End Stage Renal Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the End Stage Renal Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; End Stage Renal Disease Market Forecast

Some of the key facts of the End Stage Renal Disease Market Report: 

• The End Stage Renal Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In April 2022, Fresenius Medical Care disclosed that the FDA in the United States has given approval for the Versi PD Cycler System. This is an advanced portable automated peritoneal dialysis system now authorized for use in North America.
• In March 2022, The Health Minister inaugurated a Hemodialysis unit at New Souillac in the presence of the World Health Representative to commemorate World Kidney Day in Mauritius. This new facility incorporates 22 hemodialysis machines with a capacity to serve approximately 150 patients, intending to enhance the decentralization of treatment for individuals affected by kidney disease.
• The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry gathered information on Renal Replacement Therapy (RRT) for End-Stage Renal Disease (ESRD) by compiling data from national and regional renal registries in Europe and neighboring countries around the Mediterranean Sea.
• Gender variations have been observed within the nephrology domain, indicating that women exhibit a certain degree of protection against developing End-Stage Renal Disease (ESRD). The overall occurrence of ESRD remains relatively low during the reproductive years, with an onset occurring approximately a decade later in women compared to men.
• As of December 31, 2018, approximately 0.7 million individuals (785,883) were undergoing treatment for End-Stage Renal Disease (ESRD) in the United States, resulting in a point prevalence of 2,382 cases per million population. Among these, the prevalence of dialysis treatment was 1,685 per million, while the prevalence of a functioning kidney transplant was 696 per million, according to the Centers for Disease Control and Prevention (2022).
• TRIFERIC is the initial and sole FDA-approved therapy designed for the replenishment of iron to sustain hemoglobin levels in adult individuals with hemodialysis-dependent chronic kidney disease (HDD-CKD).
• Key End Stage Renal Disease Companies: Rockwell Medical Technologies, Aronora, Merck Sharp & Dohme, Gilead Sciences, Amgen,  Abbott, Astellas Pharma, Veloxis Pharmaceuticals, and others
• Key End Stage Renal Disease Therapies: TRIFERIC, AB002, MK-2060, Zepatier, Epclusa, Aranesp®, Erythrocyte Stimulating Agent (ESA), paricalcitol capsules, Astagraf XL, Tacrolimus, and others
• The End Stage Renal Disease epidemiology based on gender analyzed that it can be concluded that ESRD is more common in males than females.
• The End Stage Renal Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage End Stage Renal Disease pipeline products will significantly revolutionize the End Stage Renal Disease market dynamics.

End Stage Renal Disease Overview

End-Stage Renal Disease (ESRD) is the final stage of chronic kidney disease (CKD), a condition in which the kidneys gradually lose their ability to function effectively over time. In ESRD, the kidneys are severely damaged and no longer able to perform their crucial functions, such as filtering waste products and excess fluids from the blood. As a result, individuals with ESRD require ongoing medical intervention or renal replacement therapy to maintain life.

Get a Free sample for the End Stage Renal Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market

End Stage Renal Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

End Stage Renal Disease Epidemiology Segmentation:

The End Stage Renal Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of End Stage Renal Disease
• Prevalent Cases of End Stage Renal Disease by severity
• Gender-specific Prevalence of End Stage Renal Disease
• Diagnosed Cases of Episodic and Chronic End Stage Renal Disease

Download the report to understand which factors are driving End Stage Renal Disease epidemiology trends @ End Stage Renal Disease Epidemiology Forecast

End Stage Renal Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the End Stage Renal Disease market or expected to get launched during the study period. The analysis covers End Stage Renal Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the End Stage Renal Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

End Stage Renal Disease Therapies and Key Companies

• TRIFERIC: Rockwell Medical Technologies
• AB002: Aronora
• MK-2060: Merck Sharp & Dohme
• Zepatier: Merck Sharp & Dohme
• Epclusa: Gilead Sciences
• Aranesp®: Amgen
• Erythrocyte Stimulating Agent (ESA): Rockwell Medical Technologies
• paricalcitol capsules: Abbott
• Astagraf XL: Astellas Pharma
• Tacrolimus: Veloxis Pharmaceuticals

Discover more about therapies set to grab major End Stage Renal Disease market share @ End Stage Renal Disease Treatment Landscape

Scope of the End Stage Renal Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key End Stage Renal Disease Companies: Rockwell Medical Technologies, Aronora, Merck Sharp & Dohme, Gilead Sciences, Amgen, Abbott, Astellas Pharma, Veloxis Pharmaceuticals, and others
• Key End Stage Renal Disease Therapies: TRIFERIC, AB002, MK-2060, Zepatier, Epclusa, Aranesp®, Erythrocyte Stimulating Agent (ESA), paricalcitol capsules, Astagraf XL, Tacrolimus, and others
• End Stage Renal Disease Therapeutic Assessment: End Stage Renal Disease current marketed and End Stage Renal Disease emerging therapies
• End Stage Renal Disease Market Dynamics: End Stage Renal Disease market drivers and End Stage Renal Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• End Stage Renal Disease Unmet Needs, KOL’s views, Analyst’s views, End Stage Renal Disease Market Access and Reimbursement 

To know more about End Stage Renal Disease companies working in the treatment market, visit @ End Stage Renal Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. End Stage Renal Disease Market Report Introduction

2. Executive Summary for End Stage Renal Disease

3. SWOT analysis of End Stage Renal Disease

4. End Stage Renal Disease Patient Share (%) Overview at a Glance

5. End Stage Renal Disease Market Overview at a Glance

6. End Stage Renal Disease Disease Background and Overview

7. End Stage Renal Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of End Stage Renal Disease 

9. End Stage Renal Disease Current Treatment and Medical Practices

10. End Stage Renal Disease Unmet Needs

11. End Stage Renal Disease Emerging Therapies

12. End Stage Renal Disease Market Outlook

13. Country-Wise End Stage Renal Disease Market Analysis (2019–2032)

14. End Stage Renal Disease Market Access and Reimbursement of Therapies

15. End Stage Renal Disease Market Drivers

16. End Stage Renal Disease Market Barriers

17.  End Stage Renal Disease Appendix

18. End Stage Renal Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services